Iguana Healthcare Management LLC increased its stake in ObsEva SA (NASDAQ:OBSV) by 66.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 50,000 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Iguana Healthcare Management LLC owned approximately 0.17% of ObsEva worth $407,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in OBSV. VHCP Management II LLC raised its holdings in ObsEva by 834.2% in the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock worth $11,407,000 after purchasing an additional 1,251,343 shares during the period. Abingworth LLP bought a new position in ObsEva in the 3rd quarter worth $3,480,000. Sectoral Asset Management Inc raised its holdings in ObsEva by 181.9% in the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after purchasing an additional 137,331 shares during the period. Finally, Sphera Funds Management LTD. raised its holdings in ObsEva by 12.4% in the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after purchasing an additional 28,700 shares during the period. 35.91% of the stock is currently owned by institutional investors.
Shares of ObsEva SA (NASDAQ OBSV) opened at $9.77 on Friday. ObsEva SA has a 12 month low of $5.00 and a 12 month high of $14.69.
ObsEva (NASDAQ:OBSV) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.01). ObsEva’s revenue for the quarter was up NaN% compared to the same quarter last year. equities analysts anticipate that ObsEva SA will post -2.27 EPS for the current fiscal year.
A number of equities analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of ObsEva in a report on Wednesday, November 8th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $22.00 target price on shares of ObsEva in a report on Thursday, November 2nd. BMO Capital Markets began coverage on ObsEva in a research note on Monday, December 4th. They issued an “outperform” rating and a $20.00 price target for the company. Zacks Investment Research upgraded ObsEva from a “sell” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Wednesday, October 18th. Finally, Credit Suisse Group began coverage on ObsEva in a research note on Monday, October 9th. They issued an “outperform” rating and a $16.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, ObsEva has a consensus rating of “Buy” and an average target price of $19.00.
COPYRIGHT VIOLATION NOTICE: “Iguana Healthcare Management LLC Buys 20,000 Shares of ObsEva SA (OBSV)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/15/iguana-healthcare-management-llc-buys-20000-shares-of-obseva-sa-obsv.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.